AbbVie Inc. 3Y Total Assets Growth (CAGR)

3Y Total Assets Growth (CAGR) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Total Assets Growth (CAGR) growth rates and interactive chart.


Highlights and Quick Summary

  • Annual 3Y Total Assets Growth (CAGR) for 2019 was -100.0% (a -2724.67% decrease from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2018 was 3.81% (a -89.71% decrease from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2017 was 37.03% (a 18.31% increase from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Total Assets Growth (CAGR) of AbbVie Inc.

Most recent 3Y Total Assets Growth (CAGR)of ABBV including historical data for past 10 years.

Interactive Chart of 3Y Total Assets Growth (CAGR) of AbbVie Inc.

AbbVie Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -100.0%
2018 3.81%
2017 37.03%
2016 31.3%
2015 25.24%
2014 12.12%
2013 11.37%
2012 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.